SELP and diabetes mellitus: Although recent studies suggest improvements in the treatment of thrombosis in diabetes using dual‐antiplatelet therapy and direct oral anticoagulants, further studies are required to investigate the appealing potential of targeting thromboinflammatory mechanisms in diabetes, with initial trials of anti‐CD62P drugs showing promise.